Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000305
Chunk: 112

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 112
---
 SEC Documents. The Company understands and confirms that the Holder will rely on the foregoing representation
in effecting purchases and sales of securities of the Company. All of the disclosure furnished by or on behalf of the Company
by a Person authorized by the Company to the Holder regarding the Company, its business and the transactions contemplated hereby is true
and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press releases
disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made and at the time when made, not misleading. The Company acknowledges
and agrees that the Holder neither makes nor has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in hereof.

(g) . Neither the Company nor any Subsidiary has, and to the Company’s knowledge, no agent or other person acting
on behalf of the Company and each Subsidiary has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment
or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company and each Subsidiary (or made by any person acting on behalf of the Company and each Subsidiary of
which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt
Practices Act of 1977, as amended.

(h) . Neither the Company or its Subsidiaries is or, after giving effect to the offering and issuance of this Note to the Holder, will be, required to be registered as an “investment company” or an entity “controlled” by an “investment company,” as such terms are defined in the Investment Company Act of 1940, as amended.

(i) Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director